Age-related Macular Degeneration PBMC
Powered by BiozAbout:Age-related Macular Degeneration PBMC from consented donors with clinically confirmed AMD, processed within 24 hours and cryopreserved in CryoStor CS10. AMD is a degenerative retinal disease with firmly established complement genetics (CFH, C3, CFI, ARMS2/HTRA1) and mononuclear phagocyte involvement. PBMC supply both donor DNA for genotyping and the monocyte compartment for macrophage, phagocytosis and complement inhibitor studies. Stratification by stage, geographic atrophy versus neovascular subtype and treatment available.
About Age-related Macular Degeneration PBMC
Age-related Macular Degeneration PBMC for Retinal Degeneration and Complement Research
Age-related Macular Degeneration Human PBMC products are sourced from IRB-consented donors clinically diagnosed with age-related macular degeneration (AMD), processed within 24 hours of collection and cryopreserved in CryoStor CS10 freezing media. AMD is a degenerative disease of the central retina in which complement dysregulation and mononuclear phagocyte involvement are central mechanisms, rather than autoimmunity.
Why PBMC for Age-related Macular Degeneration Research
- AMD has one of the most firmly established complement genetics of any common disease. Risk variants in CFH, including the Y402H polymorphism, and in C3, CFB, C2 and CFI, together with the ARMS2/HTRA1 locus, define genetic risk, and complement components are found within drusen. PBMC provide a ready source of donor genomic DNA for genotyping alongside functional cells from the same individual.
- That complement biology is now therapeutically actionable: complement inhibition is approved for geographic atrophy. PBMC from AMD donors allow complement activation, regulation and inhibitor pharmacology to be studied in patient-derived cells that carry the relevant risk genotypes.
- Mononuclear phagocytes accumulate in the subretinal space in AMD, and circulating monocytes are the source population. PBMC contain that monocyte compartment, enabling monocyte-derived macrophage differentiation, polarisation and phagocytosis assays relevant to drusen and debris clearance.
- Altered chemokine receptor expression on circulating monocytes, involving CCR2 and CX3CR1 among others, has been reported in AMD, making PBMC-based immunophenotyping and migration assays directly relevant to the recruitment step.
- Monocytes and macrophages both produce and respond to complement components locally, so PBMC-derived cells let researchers examine the intersection of the two dominant mechanisms in the same experimental system.
- Cryopreserved PBMC support single-cell RNA sequencing, high-parameter cytometry and transcriptomic profiling of the systemic immune compartment in a disease whose primary lesion is not otherwise accessible in living donors.
Donor Stratification Available
- Disease stage: early, intermediate, or late AMD, with AREDS severity category where documented
- Late-stage subtype: geographic atrophy (dry) versus neovascular or exudative (wet) AMD, and unilateral versus bilateral involvement
- Treatment status: treatment-naive, intravitreal anti-VEGF therapy with agent and injection history, or complement inhibitor therapy for geographic atrophy
- Genotype where documented, including CFH and ARMS2 risk alleles
- Risk factor context: smoking status, AREDS2 supplement use, cardiovascular comorbidity, and visual acuity where documented
- Matched age-matched healthy controls available, and other retinal degeneration donors such as Stargardt disease for comparison
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed AMD donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor CS10 freezing media
- Viability and cell counts reported per lot
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot available prior to bulk orders
De-identified Donor Data
- Verified age-related macular degeneration diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional AMD-specific data including ophthalmological findings available upon request
Applications
- Complement pathway genotyping and genotype-to-phenotype studies using PBMC-derived DNA
- Complement activation, regulation and inhibitor pharmacology in patient-derived cells
- Monocyte-derived macrophage differentiation, polarisation and phagocytosis assays
- Monocyte subset immunophenotyping and chemokine receptor profiling
- Monocyte migration and chemotaxis assays
- Single-cell RNA sequencing and high-parameter cytometry of the systemic immune compartment
- Transcriptomic and proteomic profiling in retinal degeneration
- Therapeutic screening and target validation for dry and neovascular AMD
Other Age-related Macular Degeneration Specimen Types
- Age-related Macular Degeneration Serum
- Age-related Macular Degeneration Plasma
- Age-related Macular Degeneration Whole Blood
- Age-related Macular Degeneration Leukopak
- Stargardt Disease PBMC
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Age-related Macular Degeneration PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, or a quote on a stratified donor cohort, contact learnmore@sanguinebio.com; email us as well for international orders or regulatory documentation. To browse other disease states in this specimen type, visit our human PBMC page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), PBMC
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Age-related Macular Degeneration PBMC with normal donor samples for comparison
Healthy Donor PBMCs
705 In Stock View InventoryNeed a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.